Helex to present 3 posters at ASGCT 2024 in Baltimore covering our CRISPR Cas9 therapeutic approach for Autosomal Dominant Polycystic Kidney Disease and our drug design technology's guideRNA design and safety assessment capabilities

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.